387 related articles for article (PubMed ID: 35583664)
1. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge.
Radcliffe C; Palacios CF; Azar MM; Cohen E; Malinis M
Am J Transplant; 2022 Oct; 22(10):2458-2463. PubMed ID: 35583664
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era.
Hedvat J; Lange NW; Salerno DM; DeFilippis EM; Kovac D; Corbo H; Chen JK; Choe JY; Lee JH; Anamisis A; Jennings DL; Codispodo G; Shertel T; Brown RS; Pereira MR
Am J Transplant; 2022 Nov; 22(11):2682-2688. PubMed ID: 35801839
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
[TBL] [Abstract][Full Text] [Related]
6. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
7. Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge.
Avery RK
Transplantation; 2022 Aug; 106(8):1528-1537. PubMed ID: 35700481
[TBL] [Abstract][Full Text] [Related]
8. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
[No Abstract] [Full Text] [Related]
9. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
10. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
Mazzotta V; Cozzi Lepri A; Colavita F; Rosati S; Lalle E; Cimaglia C; Paulicelli J; Mastrorosa I; Vita S; Fabeni L; Vergori A; Maffongelli G; Carletti F; Lanini S; Caraffa E; Milozzi E; Libertone R; Piselli P; Girardi E; Garbuglia A; Vaia F; Maggi F; Nicastri E; Antinori A;
J Med Virol; 2023 Jan; 95(1):e28186. PubMed ID: 36184918
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
12. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
Atmar RL; Finch N
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
[TBL] [Abstract][Full Text] [Related]
13. A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients.
Ahearn AJ; Thin Maw T; Mehta R; Emamaullee J; Kim J; Blodget E; Kahn J; Sher L; Genyk Y
Transplantation; 2022 Feb; 106(2):e153-e157. PubMed ID: 34519680
[TBL] [Abstract][Full Text] [Related]
14. Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy.
Ciccimarra F; Luxi N; Bellitto C; L' Abbate L; De Nardo P; Savoldi A; Yeomans A; Molokhia M; Tacconelli E; Trifirò G
BioDrugs; 2023 Sep; 37(5):675-684. PubMed ID: 37148526
[TBL] [Abstract][Full Text] [Related]
15. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
16. Coronavirus Disease 2019 Management Strategies in Solid Organ Transplant Recipients.
Mendoza MA; Razonable RR
Infect Dis Clin North Am; 2023 Sep; 37(3):475-493. PubMed ID: 37142512
[TBL] [Abstract][Full Text] [Related]
17. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
Tang Y; Li Y; Song T
Front Immunol; 2023; 14():1150341. PubMed ID: 37081880
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic.
Denning K; Sheppard J; Carico R
J Am Pharm Assoc (2003); 2024; 64(2):530-534. PubMed ID: 38151202
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 infection in solid organ transplant recipients: Experience with molnupiravir.
Villamarín M; Len O
Rev Esp Quimioter; 2023 Nov; 36 Suppl 1(Suppl 1):22-24. PubMed ID: 37997866
[TBL] [Abstract][Full Text] [Related]
20. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]